Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Xenon Pharmaceuticals Inc is a biotechnology business based in the US. Xenon Pharmaceuticals shares (XENE) are listed on the NASDAQ and all prices are listed in US Dollars. Xenon Pharmaceuticals employs 123 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $26.00 |
|---|---|
| 52-week range | $13.98 - $36.42 |
| 50-day moving average | $29.46 |
| 200-day moving average | $22.35 |
| Wall St. target price | $45.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.55 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $26 from 2022-01-21
| 1 week (2022-01-14) | -18.65% |
|---|---|
| 1 month (2021-12-21) | N/A |
| 3 months (2021-10-25) | -15.39% |
| 6 months (2021-07-23) | 42.08% |
| 1 year (2021-01-25) | 62.81% |
|---|---|
| 2 years (2020-01-24) | 67.74% |
| 3 years (2019-01-24) | 232.91% |
| 5 years (2017-01-24) | 222.98% |
| Revenue TTM | $19.9 million |
|---|---|
| Gross profit TTM | $-18,357,000 |
| Return on assets TTM | -18.09% |
| Return on equity TTM | -30.46% |
| Profit margin | 0% |
| Book value | $5.87 |
| Market capitalisation | $1.7 billion |
TTM: trailing 12 months
We're not expecting Xenon Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Xenon Pharmaceuticals's shares have ranged in value from as little as $13.9827 up to $36.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xenon Pharmaceuticals's is 1.8956. This would suggest that Xenon Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xenon Pharmaceuticals Inc. , a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1. 6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.